Diabetes with Cardiovascular and Kidney Complications

Learning Objectives: 

•    Recall current guidelines for the management of people with type 2 diabetes and chronic kidney disease (CKD).
•    Identify options to reduce cardiovascular (CV) risk in people with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD).
•    Summarize the evidence supporting the use of sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment for patients with heart failure with reduced ejection fraction (HFrEF).